Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | NCF1 | P14598 | 2/20 | 0.54 |
| ▸ | F12 | P00748 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | NOS3 | P29474 | 1/20 | 0.54 |
| ▸ | NOS1 | P29475 | 1/20 | 0.54 |
| ▸ | NOS2 | P35228 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14931471 | 1.00 | ALDH1A1 (0.59) | ALDH1A1CYP3A4HPGDTSHRHSD17B10 | |
| Hydrochloric Acid SCHEMBL28196297 | 0.98 | CYP3A4 (0.56) | ALDH1A1CYP3A4HPGDTSHRHSD17B10 | |
| SCHEMBL16006827 | 0.78 | CYP1A2 (0.54) | ALDH1A1NCF1F12PLAUNOS3 | |
| SCHEMBL10686979 | 0.78 | CYP1A2 (0.54) | ALDH1A1TDP1NCF1F12PLAU | |
| SCHEMBL31339851 | 0.78 | CYP3A4 (0.54) | ALDH1A1CYP3A4HPGDTSHRHSD17B10 | |
| SCHEMBL24196655 | 0.78 | NOS3 (0.50) | ALDH1A1CYP3A4HPGDHSD17B10TDP1 | |
| SCHEMBL564739 | 0.78 | CYP3A4 (0.54) | ALDH1A1CYP3A4HPGDTSHRHSD17B10 | |
| SCHEMBL2673211 | 0.78 | PLAU (0.54) | ALDH1A1TDP1NCF1F12PLAU | |
| SCHEMBL2380637 | 0.78 | CYP3A4 (0.54) | ALDH1A1CYP3A4HPGDTSHRHSD17B10 | |
| SCHEMBL31165790 | 0.78 | ALDH1A1 (0.54) | ALDH1A1CYP3A4HPGDTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478970-B | Precursor composition of covalent organic framework material and application thereof | 中国科学院大连化学物理研究所 | 2023-11-03 | — | — | CN | claimed |
| CN-114478970-A | Precursor composition of covalent organic framework material and application thereof | 中国科学院大连化学物理研究所 | 2022-05-13 | — | — | CN | claimed |
| EP-4475851-A1 | FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF ACTIVE AGENTS | Dyve Biosciences, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-4362949-A2 | USE OF ISOQUINOLINE-1,5-DIAMINES FOR WOUND HEALING | Lutris Pharma Ltd. (IL) | 2024-05-08 | — | — | EP | disclosed |
| CN-114478970-B | Precursor composition of covalent organic framework material and application thereof | 中国科学院大连化学物理研究所 | 2023-11-03 | — | — | CN | disclosed |
| EP-4267144-A1 | TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF EGFR DOWNSTREAM EFFECTORS - INDUCED REACTIONS | Lutris Pharma Ltd. (IL) | 2023-11-01 | — | — | EP | disclosed |
| US-20230321106-A1 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF EPIDERMAL GROWTH FACTOR RECEPTOR DOWNSTREAM EFFECTORS - INDUCED CUTANEOUS REACTIONS | LUTRIS PHARMA LTD. (IL) | 2023-10-12 | — | — | US | disclosed |
| CN-116745278-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116669739-A | Topical BRAF inhibitor compositions for the treatment of EGFR downstream effector-induced responses | 鲁特里斯制药有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2023154479-A1 | FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF ACTIVE AGENTS | DYVE BIOSCIENCES, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023275620-A2 | USE OF ISOQUINOLINE-1,5-DIAMINES FOR WOUND HEALING | LUTRIS PHARMA LTD. (IL) | 2023-01-05 | — | — | WO | disclosed |
| US-20220298141-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| WO-2022136912-A1 | TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF EGFR DOWNSTREAM EFFECTORS - INDUCED REACTIONS | LUTRIS PHARMA LTD. (IL) | 2022-06-30 | — | — | WO | disclosed |
| EP-4017849-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| CN-114478970-A | Precursor composition of covalent organic framework material and application thereof | 中国科学院大连化学物理研究所 | 2022-05-13 | — | — | CN | disclosed |
| CN-114286820-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-04-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298141-A1 | ENZYME INHIBITORS | SERPINB1, ACE, GAA | ALDH1A1 141/4885CYP3A4 24/4885HPGD 238/4885 |
| US-20230321106-A1 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF EPIDERMAL GROWTH FACTOR RECEPTOR DOWNSTREAM EFFECTORS - INDUCED CUTANEOUS REACTIONS | BRAF, ERBB3, EGFR | ALDH1A1 2972/4885CYP3A4 794/4885HPGD 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.